PLoS ONE (Jan 2020)

External quality assessment of Rift Valley fever diagnosis in 17 veterinary laboratories of the Mediterranean and Black Sea regions.

  • Elisa Pérez-Ramírez,
  • Cristina Cano-Gómez,
  • Francisco Llorente,
  • Bojan Adzic,
  • Maisa Al Ameer,
  • Igor Djadjovski,
  • Jeanne El Hage,
  • Fatiha El Mellouli,
  • Teufik Goletic,
  • Hermine Hovsepyan,
  • Ilke Karayel-Hacioglu,
  • Jelena Maksimovic Zoric,
  • Selma Mejri,
  • Hassiba Sadaoui,
  • Sayed Hassan Salem,
  • Kurtesh Sherifi,
  • Natela Toklikishvili,
  • Ani Vodica,
  • Federica Monaco,
  • Alejandro Brun,
  • Miguel Ángel Jiménez-Clavero,
  • Jovita Fernández-Pinero

DOI
https://doi.org/10.1371/journal.pone.0239478
Journal volume & issue
Vol. 15, no. 9
p. e0239478

Abstract

Read online

Rift Valley fever (RVF) is an arboviral zoonosis that primarily affects ruminants but can also cause illness in humans. The increasing impact of RVF in Africa and Middle East and the risk of expansion to other areas such as Europe, where competent mosquitos are already established, require the implementation of efficient surveillance programs in animal populations. For that, it is pivotal to regularly assess the performance of existing diagnostic tests and to evaluate the capacity of veterinary labs of endemic and non-endemic countries to detect the infection in an accurate and timely manner. In this context, the animal virology network of the MediLabSecure project organized between October 2016 and March 2017 an external quality assessment (EQA) to evaluate the RVF diagnostic capacities of beneficiary veterinary labs. This EQA was conceived as the last step of a training curriculum that included 2 diagnostic workshops that were organized by INIA-CISA (Spain) in 2015 and 2016. Seventeen veterinary diagnostic labs from 17 countries in the Mediterranean and Black Sea regions participated in this EQA. The exercise consisted of two panels of samples for molecular and serological detection of the virus. The laboratories were also provided with positive controls and all the kits and reagents necessary to perform the recommended diagnostic techniques. All the labs were able to apply the different protocols and to provide the results on time. The performance was good in the molecular panel with 70.6% of participants reporting 100% correct results, and excellent in the serological panel with 100% correct results reported by 94.1% of the labs. This EQA provided a good overview of the RVFV diagnostic capacities of the involved labs and demonstrated that most of them were able to correctly identify the virus genome and antibodies in different animal samples.